IPF patients treated with Ofev® (nintedanib) versus placebo were twice as likely to have improved or stable lung function
IPF patients treated with Ofev® (nintedanib) versus placebo were twice as likely to have improved or stable lung function
Search
Outlook for Partnering in Animal Health 2024
Megan Grether, Head of Business Development & Licensing for Animal Health, shares her perspectives on the year ahead for partnering in Animal Health.
Landmark trial demonstrates Jardiance® (empagliflozin) is the first therapy to show statistically significant improvement in heart failure outcomes in adults with preserved ejection fraction
Landmark trial demonstrates Jardiance® (empagliflozin) is the first therapy to show statistically significant improvement in heart failure outcomes in adults with preserved ejection fraction
Efficacy and safety of Ofev® (nintedanib) reinforced in new presentations at ATS 2018
Efficacy and safety of Ofev® (nintedanib) reinforced in new presentations at ATS 2018
Full results from EMPERIAL exercise ability trials presented
Full results from EMPERIAL exercise ability trials presented
FDA Provides Full Approval to Praxbind, Specific Reversal Agent for Pradaxa
FDA Provides Full Approval to Praxbind, Specific Reversal Agent for Pradaxa
Building Successful Partnerships in Animal Health
Christoph Vetten, Head of Transactions Animal Health, shares his perspectives on how building successful collaborations can drive innovation.
SPEVIGO approved for expanded indications in China and the US
FDA approval for the Treatment of Generalized Pustular Psoriasis (GPP) in Adults and Pediatric Patients 12 Years of Age and Older Weighing at Least 40kg
FDA accepts sNDA for children/adolescents with fibrosing ILD
U.S. FDA accepts sNDA for OFEV® (nintedanib) for the potential treatment of children and adolescents aged 6-17 with fibrosing interstitial lung disease
Jardiance® (empagliflozin) Proven to Reduce Risk of Cardiovascular Death | BI US
Find out more about how the use of JARDIANCE has proven to reduce the combined relative risk of cardiovascular death and hospitalization for heart failure by 25%.
Phase III EMPA-KIDNEY trial will stop early
The EMPA-KIDNEY trial, evaluating the effect of Jardiance (empagliflozin) tablets in adults with chronic kidney disease (CKD), will stop early based on a recommendation from the trial’s Independent Data Monitoring Committee.
Intensive education about multidisciplinary care improved likelihood that adults with type 2 diabetes and cardiovascular disease were receiving guideline-directed medicines
The findings demonstrate the benefit of clinic-level educational interventions
Scam alert
Scam alert
U.S. FDA approves supplemental New Drug Applications to include landmark data in product labels for Synjardy® (empagliflozin/metformin hydrochloride), Synjardy® XR (empagliflozin/metformin hydrochloride extended-release) and Glyxambi® (empagliflozin/linag
U.S. FDA approves supplemental New Drug Applications to include landmark data in product labels for Synjardy® (empagliflozin/metformin hydrochloride), Synjardy® XR (empagliflozin/metformin hydrochloride extended-release) and Glyxambi® (empagliflozin/linag
Ofev® demonstrates consistent long-term efficacy in IPF regardless of baseline lung function
Ofev® demonstrates consistent long-term efficacy in IPF regardless of baseline lung function
Taking patient centricity to new heights
Learn about how we focus on putting patients first and finding solutions to meet their healthcare needs.
A sense of community and a love for gardening that’s lasted decades at our U.S. headquarters
Discover our longstanding love for gardening and how it started with Schatzi’s chives.
New study results provide evidence that Ofev® (nintedanib) slows progression of IPF beyond four years with consistent safety
New study results provide evidence that Ofev® (nintedanib) slows progression of IPF beyond four years with consistent safety
Full data announced in phase III EMPA-KIDNEY trial
The EMPA-KIDNEY phase III clinical trial met its primary endpoint by demonstrating a significant kidney and cardiovascular benefit for adults living with chronic kidney disease (CKD)
Sustainable cattle production: Feeding the world while minimizing environmental effect
Sustainable cattle production: Feeding the world while minimizing environmental effect
Ordering your medicine online? Find a safe pharmacy first.
Learn what to look for when buying medication and how to verify your pharmacy.
Full data announced in DINAMO trial in young people with T2D
Jardiance (empagliflozin) tablets is the first SGLT2 inhibitor to show statistically significant
When Passion Starts as a Family Value and Continues as a Work Value
Discover who inspires members of our LatinX Business Resource Group.
Shelter Bowl: These pets looking for a new home were the big winners
Dogs and cats in a pair of shelters were met with generous donations – and some footballs - thanks to a program committed to improving their future and well-being.
Spesolimab prevented generalized pustular psoriasis flares in Effisayil™ 2 trial
Spesolimab prevented generalized pustular psoriasis flares in Effisayil™ 2 trial